A combination of the kinase-inhibitor drug cabozantinib and the immunotherapy drug nivolumab can make curative surgery possible in some liver cancer patients who would normally not be considered surgery candidates.
Results published July 29 in the journal Nature…
- Business21 hours ago
Is the South32 (ASX:S32) share price a buy for dividends?
- Local News21 hours ago
Victorian cases climb to 603, as construction is shut down
- Local News22 hours ago
The Moderna Vaccine Is Being Rolled Out Through Australian Pharmacies From This Week
- Local News24 hours ago
New charges laid in relation to Eastern Freeway crash after 18-month investigation